Drug Profile
Efineptakin alfa - Genexine
Alternative Names: Efineptakin alfa NT-I7; GX I7; HyLeukin; HyLeukin-7™; IL-7 Hybrid Fc; IL-7-hyFc; Interleukin-7-hybrid-Fc-recombinant-protein; NT I7; Recombinant human IL-7-hyFc; Recombinant human interleukin-7 hybrid Fc; rhIL-7 - Genexine/I-MAB Biopharma; rhIL-7-hyFc; TJ 107Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Genexine
- Developer Bristol-Myers Squibb; Fred Hutchinson Cancer Research Center; Genexine; I-MAB Biopharma; Merck & Co; National Cancer Institute (USA); National Institute of Neurological Disorders and Stroke; NeoImmuneTech; PT Kalbe Genexine Biologics; Roche; Yonsei University
- Class Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Radioprotectives; Recombinant fusion proteins; Recombinant proteins
- Mechanism of Action Interleukin 7 replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Adenocarcinoma; COVID 2019 infections; Glioblastoma; Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
- Phase I/II Pancreatic cancer; Skin cancer; Small cell lung cancer; Solid tumours
- Phase I Anal cancer; Biliary cancer; Cervical cancer; Diffuse large B cell lymphoma; Kaposi's sarcoma; Ovarian cancer; Progressive multifocal leukoencephalopathy
- Preclinical Acute radiation syndrome
- No development reported Bladder cancer; Breast cancer; Cervical intraepithelial neoplasia; Colorectal cancer; Human papillomavirus infections; Idiopathic CD4-positive T-lymphocytopenia; Lymphoma
Most Recent Events
- 09 Apr 2024 Pharmacodynamics data from a preclinical trial in Colorectal cancer released by NeoImmuneTech
- 09 Apr 2024 NeoImmuneTech plans a clinical trial in Hematologic malignancies, Solid tumors and Immunological disorders
- 28 Mar 2024 No recent reports of development identified for phase-I development in COVID-2019-infections in South Korea (IM, Injection)